LARGER VIALS = LARGER SAVINGS PER mg

Semaglutide

Semaglutide

$52.00
$52.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

Semaglutide

Semaglutide

$52.00
$52.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. It is FDA-approved for the treatment of type 2 diabetes and chronic weight management, with clinical studies demonstrating substantial efficacy in improving glycemic control and reducing body weight.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) used in research and clinical applications for type 2 diabetes and obesity. As a modified analogue of native GLP-1, it is resistant to degradation by dipeptidyl peptidase-4 (DPP-4), resulting in a half-life of ~7 days that allows once-weekly dosing. Semaglutide reduces blood glucose, appetite, and body weight while improving cardiometabolic risk factors.

Structure

  • Type: Modified GLP-1 analogue
  • Molecular Weight: ~4113 Da
  • Modifications:

    Substitution at position 8 (Aib for Ala) → DPP-4 resistance



    C18 fatty diacid chain at Lys26 → albumin binding, extended half-life

  • Mechanism:



    Activates GLP-1 receptors in the pancreas and brain



    Enhances glucose-dependent insulin secretion



    Suppresses glucagon release, gastric emptying, and appetite

Research

Type 2 Diabetes

  • Improves glycemic control and reduces HbA1c significantly.
  • Reduces risk of diabetes complications by improving metabolic health.

Obesity & Weight Management

  • Produces substantial weight loss through appetite suppression and reduced caloric intake.
  • STEP trials demonstrated mean reductions of ~15% body weight over 68 weeks in obese adults.

Cardiovascular Outcomes

  • In the SUSTAIN-6 trial, semaglutide reduced risk of major adverse cardiovascular events (MACE) in type 2 diabetes patients.
  • Improves blood pressure, lipid profiles, and inflammation markers.

Additional Research

  • Investigated in non-alcoholic steatohepatitis (NASH), PCOS, and neurodegenerative diseases.
  • Potential benefits in renal protection.

Safety Profile

  • Most common effects: nausea, vomiting, diarrhea, constipation (dose-dependent, transient).
  • Rare risks: gallbladder disease, pancreatitis, and potential thyroid C-cell tumors (in rodent studies).

Summary

Semaglutide is a long-acting GLP-1 analogue with major roles in:

  • Type 2 diabetes management
  • Obesity and weight reduction
  • Cardiovascular and metabolic health
  • Emerging research in liver disease and neuroprotection

This peptide is supplied as a lyophilized powder. Store vials at 2–8 °C, protected from light and moisture. For long-term preservation, keep unopened vials at −20 °C. After reconstitution, prepare solutions under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141

2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183

3. Davies M, et al. Semaglutide as a treatment for type 2 diabetes: SUSTAIN trials. *Lancet Diabetes Endocrinol*. 2017;5(4):341–354. doi:10.1016/S2213-8587(17)30092-5

4. Kushner RF, et al. Semaglutide in adults with overweight or obesity: STEP trials overview. *Obesity (Silver Spring)*. 2020;28(6):1050–1061. doi:10.1002/oby.22802

5. Lingvay I, et al. Semaglutide vs placebo and cardiovascular outcomes: SUSTAIN-6 extension. *Diabetes Obes Metab*. 2019;21(7):1576–1584. doi:10.1111/dom.13689

6. Newsome PN, et al. Semaglutide in patients with NASH: a randomized trial. *Lancet*. 2021;398(10302): 345–356. doi:10.1016/S0140-6736(21)01324-6

7. Pratley RE, et al. Efficacy and safety of semaglutide monotherapy in type 2 diabetes. *Lancet Diabetes Endocrinol*. 2017;5(4):251–260. doi:10.1016/S2213-8587(17)30013-X

8. Rubino DM, et al. Weight reduction with semaglutide in obesity without diabetes. *Diabetes Care*. 2021;44(2):350–358. doi:10.2337/dc20-2570

9. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. *Diabetes Obes Metab*. 2018;20(S1):5–21. doi:10.1111/dom.13129

10. Drucker DJ. Mechanisms of action and therapeutic application of GLP-1 receptor agonists. *Cell Metab*. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001